Radiotherapy in the treatment of middle ear and mastoid carcinoma.
The treatment of temporal bone carcinoma is a widely discussed topic with marked variation in published results. Most conclude that a combination of radical surgery and radiotherapy is the optimum treatment. The present study reviews the results of radiotherapy used as the main primary treatment for this condition. Five-year survival in 56 patients was 32% for radical and palliative therapy, with an excellent response in 'early' cases. It is concluded that improvement in survival could be attained by defining those groups which would benefit from a combination of treatment methods.
Birzgalis
A R
AR
University Department of Otolaryngology, Manchester Royal Infirmary, UK.
Keith
A O
AO
Farrington
W T
WT
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D004428:Ear Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D004432:Ear, Middle / Q000528:radiation effects*; D005260:Female; D006801:Humans; D008297:Male; D008416:Mastoid / Q000528:radiation effects*; D008875:Middle Aged; D009367:Neoplasm Staging; D010166:Palliative Care; D011882:Radiotherapy, High-Energy; D012888:Skull Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D015996:Survival Rate